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Rationale
To compare the relative potency in skin tests of solution
and tablet extracts of Timothy grass pollen (TIM) of 2
European manufacturers (ALK-Abelló, Stallergènes),
with an FDA approved extract (REF) of 10,000BAU/mL.
Methods
This is a prospective, multicenter, triple blinded, rando-
mized study in which the in vivo extract potency was
determined, based on the wheal size obtained in TIM
allergic patients. The four tested TIM extracts were:
Soluprick, Staloral 300IR, and Grazax and Oralair 300IR
dissolved in 1mL 50% glycerin (under GMP standards).
The SPTs were carried out in quadruplicate with the
concentrate extracts and three serial half-log dilutions,
and +/- controls. The study took place at study sites
with different climatologic conditions. To determine if
there exists a statistically significant difference between
the relative potency of the TIM extracts a parallel line
bioassay was carried out using the mean surface of the
four wheals of the SPTs per extract and per concentra-
tion (Wilcoxon, Asymp. Sig.(2-tailed)). Based on the
wheal sizes of the concentrate extracts in relation to the
REF, BAU values were calculated.
Results
Differences in wheal size between concentrate extracts
reached statistical significance for all, except Soluprick-
REF. The calculated BAU compared to the REF values
for both solutions were between 11,300-16,300BAU/mL
and the tablets varied between 4200-7300 BAU.
Conclusions
Based on SPT whealsizes grass-tablets seem to have a
higher relative potency than the previously published
value of 2800BAU (which was based on in vitro testing).
There is a statistically significant difference (p=0.011)
between the allergen concentration as measured in SPT
of both tablets. Probably other factors apart from the
precise allergen content of the tablets and their potency
determine the efficacy of sublingual immunotherapy.
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